May 19, 2020 / 9:52 PM / 8 days ago

BRIEF-Arch Biopartners Expands Main Goal Of Phase II Trial For Lead Drug LSALT Peptide In Patients With COVID-19

May 19 (Reuters) - Arch Biopartners Inc:

* ARCH BIOPARTNERS EXPANDS THE PRIMARY ENDPOINT OF ITS PHASE II TRIAL TO INCLUDE PREVENTION OF MULTIPLE ORGAN INJURIES IN PATIENTS WITH COVID-19

* ARCH BIOPARTNERS - PHASE II TRIAL EXPECTED TO COMMENCE IN SUMMER OF 2020

* ARCH BIOPARTNERS INC - PRIMARY ENDPOINT OF PHASE II TRIAL NOW INCLUDES ACUTE KIDNEY INJURY , CARDIOMYOPATHY, AS COMPONENTS, IN COVID-19 PATIENTS

* ARCH - PRIMARY ENDPOINT OF PHASE II TRIAL INCLUDES ACUTE LIVER INJURY, COAGULOPATHY, ALL-CAUSE MORTALITY, AS COMPONENTS, IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below